A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Evofosfamide (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms MAESTRO
- Sponsors EMD Serono; Merck KGaA; Merck Serono; Threshold Pharmaceuticals
- 21 Jun 2018 According to a Caris Life Sciences media release, results were presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2018 (ESMO GI).
- 21 Jun 2018 Results presented in a Caris Life Sciences media release.
- 05 Jun 2018 Results assessing pharmacokinetics presented at the 54th Annual Meeting of the American Society of Clinical Oncology